Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma.

Heemann C, Kreuz M, Stoller I, Schoof N, von Bonin F, Ziepert M, Löffler M, Jung W, Pfreundschuh M, Trümper L, Kube D.

Clin Cancer Res. 2012 Jul 1;18(13):3637-47. doi: 10.1158/1078-0432.CCR-11-3299. Epub 2012 May 9.

2.

Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.

Goto N, Tsurumi H, Takemura M, Hara T, Sawada M, Kasahara S, Kanemura N, Yamada T, Shimizu M, Takahashi T, Tomita E, Seishima M, Takami T, Moriwaki H.

Eur J Haematol. 2006 Sep;77(3):217-25. Epub 2006 Jul 19.

PMID:
16856931
3.

Cytokine and cytokine receptor serum levels in adult bone sarcoma patients: correlations with local tumor extent and prognosis.

Rutkowski P, Kamińska J, Kowalska M, Ruka W, Steffen J.

J Surg Oncol. 2003 Nov;84(3):151-9.

PMID:
14598359
4.

Prognostic value of serum IL-10 and soluble IL-2 receptor levels in aggressive non-Hodgkin's lymphoma.

Stasi R, Zinzani PL, Galieni P, Lauta VM, Damasio E, Dispensa E, Dammacco F, Papa G, Tura S.

Br J Haematol. 1994 Dec;88(4):770-7.

PMID:
7819101
5.

sTNFRI and sTNFRII synthesis by fine-needle aspiration biopsy sample cultures is significantly associated with acute rejection in kidney transplantation.

Oliveira JG, Xavier P, Sampaio SM, Mendes AA, Pestana M.

Transplantation. 2001 Jun 27;71(12):1835-9.

PMID:
11455266
6.

Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.

Kube D, Hua TD, von Bonin F, Schoof N, Zeynalova S, Klöss M, Gocht D, Potthoff B, Tzvetkov M, Brockmöller J, Löffler M, Pfreundschuh M, Trümper L.

Clin Cancer Res. 2008 Jun 15;14(12):3777-84. doi: 10.1158/1078-0432.CCR-07-5182.

7.

Serum-soluble interleukin-2 receptor (sIL-2R) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma: in combination with the International Prognostic Index.

Goto H, Tsurumi H, Takemura M, Ino-Shimomura Y, Kasahara S, Sawada M, Yamada T, Hara T, Fukuno K, Goto N, Okuno M, Takami T, Seishima M, Moriwaki H.

J Cancer Res Clin Oncol. 2005 Feb;131(2):73-9. Epub 2004 Oct 21.

PMID:
15503137
8.
9.

Plasma TNF-alpha and IL-10 level-based prognostic model predicts outcome of patients with diffuse large B-Cell lymphoma in different risk groups defined by the International Prognostic Index.

Lech-Maranda E, Bienvenu J, Broussais-Guillaumot F, Warzocha K, Michallet AS, Robak T, Coiffier B, Salles G.

Arch Immunol Ther Exp (Warsz). 2010 Apr;58(2):131-41. doi: 10.1007/s00005-010-0066-1. Epub 2010 Feb 27.

PMID:
20191326
10.

Interleukin-10 gene polymorphism influences the prognosis of T-cell non-Hodgkin lymphomas.

Lee JJ, Kim DH, Lee NY, Sohn SK, Kim JG, Kim HJ, Do YR, Park YH.

Br J Haematol. 2007 May;137(4):329-36. Epub 2007 Apr 4.

PMID:
17408400
11.
12.

Serum-soluble interleukin-2 receptor (sIL-2R) is an extremely strong prognostic factor for patients with peripheral T-cell lymphoma, unspecified (PTCL-U).

Kitagawa J, Hara T, Tsurumi H, Goto N, Kanemura N, Yoshikawa T, Kasahara S, Yamada T, Sawada M, Takahashi T, Shimizu M, Takami T, Moriwaki H.

J Cancer Res Clin Oncol. 2009 Jan;135(1):53-9. doi: 10.1007/s00432-008-0440-0. Epub 2008 Jul 1.

PMID:
18592269
13.

Ferritin levels, inflammatory biomarkers, and mortality in peripheral arterial disease: a substudy of the Iron (Fe) and Atherosclerosis Study (FeAST) Trial.

Depalma RG, Hayes VW, Chow BK, Shamayeva G, May PE, Zacharski LR.

J Vasc Surg. 2010 Jun;51(6):1498-503. doi: 10.1016/j.jvs.2009.12.068. Epub 2010 Mar 20.

14.

Multiplex analysis of blood cytokines as a prognostic tool in HIV related non-Hodgkin lymphoma patients: a potential role of interleukin-7.

Bortolin MT, Tedeschi R, Bidoli E, Zanussi S, Pratesi C, Vaccher E, Tirelli U, De Paoli P.

Cytokine. 2012 Oct;60(1):90-5. doi: 10.1016/j.cyto.2012.06.022. Epub 2012 Jul 12.

PMID:
22795293
15.
16.

Impact of continuous hemofiltration on cytokines and cytokine inhibitors in oliguric patients suffering from systemic inflammatory response syndrome.

van Bommel EF, Hesse CJ, Jutte NH, Zietse R, Bruining HA, Weimar W.

Ren Fail. 1997 May;19(3):443-54.

PMID:
9154661
17.

Serum levels of p55 and p75 soluble TNF receptors in adult acute leukaemia at diagnosis: correlation with clinical and biological features and outcome.

Vinante F, Rigo A, Tecchio C, Morosato L, Nadali G, Ricetti MM, Krampera M, Zanolin E, Locatelli F, Gallati H, Chilosi M, Pizzolo G.

Br J Haematol. 1998 Sep;102(4):1025-34.

PMID:
9734654
18.

Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.

Raziuddin S, Sheikha A, Abu-Eshy S, al-Janadi M.

Cancer. 1994 May 1;73(9):2426-31.

19.
20.

Circulating TNFRI and TNFRII levels correlated with the disease activity score (DAS28) in rheumatoid arthritis.

Valle Y, Ledezma-Lozano IY, Torres-Carrillo N, Padilla-Gutiérrez JR, Navarro-Hernández RE, Vázquez-Del Mercado M, Palafox-Sánchez CA, Armendáriz-Borunda J, Muñoz-Valle JF.

Scand J Rheumatol. 2009;38(5):332-5. doi: 10.1080/03009740902865456.

PMID:
19579138

Supplemental Content

Support Center